The Progression Patterns and Subsequent Treatments of First-Line Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study.

Thorac Cancer · 2025 · PMC12522518 · PMID 41091025

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, for patients with oligoprogression, the PPS showed a trend of benefit in patients receiving ICIs, but the difference was not statistically significant (47.8 vs. 20.3 months, p = 0.222) (Figure 5B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.